RxDoctor Payments Data

Millie Kooistra

Family · Terre Haute, INNPI 1295279958

Payments from drug & device makers

$5,046in general payments, 2019–2025

Across 254 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$860
  • Novo Nordisk$724
  • AstraZeneca$500
  • Corcept Therapeutics$438
  • Lilly USA, LLC$366
  • AbbVie$344
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,99499%
  • Education$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,046 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$774,240
Medicare patients
115
Services billed
62,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide51$140,071
Evenity (2 Syringes)Romosozumab-Aqqg39$94,396
OzempicSemaglutide68$80,266
ForteoTeriparatide19$75,999
ProliaDenosumab36$63,106
MounjaroTirzepatide29$39,492
WegovySemaglutide13$18,293
Celecoxib36$2,102
Levothyroxine Sodium73$890
Varenicline Tartrate11$884
Duloxetine Hcl12$704
Metoprolol Succinate22$320
Pregabalin13$280
Atorvastatin Calcium38$246
Ondansetron OdtOndansetron20$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEvenity (2 Syringes), Prolia$860$157,50275 claims
Radius Health, Inc.Tymlos$242$140,07151 claims
Lilly USA, LLCForteo, Mounjaro$366$115,49248 claims
Novo NordiskOzempic, Wegovy$724$98,55981 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$89073 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.

Other family in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →